{"filings":[{"id":1360557,"accession_number":"0001534969-26-000035","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-06-30T20:09:46+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sera Prognostics appoints Mark Capone to Board of Directors effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Capone appointed as Class II director effective July 1, 2026, and to the Compensation Committee.","Capone is former CEO of Myriad Genetics with 40+ years in diagnostics and life sciences.","Initial equity award of $167,072 (or 150,000 option equivalents) granted July 10, 2026, with multi-year vesting.","Annual equity awards of $88,359 (or 75,000 option equivalents) after each annual meeting, vesting over one year.","Board determined Capone is independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863317,"accession_number":"0001534969-26-000032","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-06-04T21:13:10+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics shareholders elect directors Kamdar and Lawrence, ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kim Kamdar, Ph.D. elected with 9,749,623 votes for; 3,062,352 withheld; 12,961,228 broker non-votes.","Sandra A. J. Lawrence elected with 12,483,966 votes for; 328,009 withheld; 12,961,228 broker non-votes.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 24,917,046 for, 856,113 against, 44 abstentions.","Quorum of 25,773,203 shares (67.5% of eligible) present at June 4, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":779356,"accession_number":"0001534969-26-000028","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-06-01T20:44:21+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sera Prognostics director Jeff Elliott resigns ahead of annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Elliott notified Board of resignation effective June 4, 2026; not due to any disagreement.","Elliott's term was expiring at Annual Meeting; he was not a nominee for re-election.","Board reduced size to seven directors following resignation.","Company in advanced discussions with candidates to fill vacancy; expects near-term appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93508,"accession_number":"0001534969-26-000024","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.","PRIME trial (5,018 women) showed PreTRM test cut early preterm births 56% (<32 wks) and 32% (<35 wks); NICU admissions down 20%.","Cash and securities $86.8M; cash runway extended through 2029 via cost restructuring.","Launched third physician partnership; active payer discussions with 13 payers across 15 states.","CE marking submission for Europe on track for mid-2026; expanding European evidence base."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105196,"accession_number":"0001534969-26-000008","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.","Revenue minimal: $10k Q4, $81k full year; company remains pre-commercial.","Cash $95.8M at Dec 31, 2025; expects to fund operations through 2028.","PRIME study published Jan 2026: PreTRM test reduced preterm births <32 wks by 56%, NICU admissions by 20%.","Completed $57.5M follow-on offering Feb 2025; added CMO Dr. Inglis, CCO Anderson in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105195,"accession_number":"0001193125-26-007850","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics posts investor presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on Jan 8, 2026; only title slide 'Redefining pregnancy care to reduce preterm birth' available.","No financial results, revised guidance, or new business milestones included in the filing.","Presentation appears to be a routine update with no substantive new information.","Company trades as SERA on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105194,"accession_number":"0001193125-26-005531","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.","20% reduction in NICU admissions and neonatal morbidity odds.","One NICU day saved per 4.2 patients screened; number needed to screen for NICU admission: 39.","Study published in Pregnancy journal (Society for Maternal-Fetal Medicine).","Jefferies fireside chat on Jan 9, 2026 at 8:30 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121449,"accession_number":"0001193125-25-292074","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics announces PRIME preterm-birth study accepted for peer-reviewed publication","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRIME study findings accepted for publication, following late-breaking abstract at SMFM annual meeting in 2025.","Study is one of the largest on preterm birth evaluating risk assessment plus clinical interventions.","Company expects to share manuscript data at medical meetings and with research analysts.","No financial terms or specific study results disclosed in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121448,"accession_number":"0001193125-25-280167","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Q3 revenue $16k, net loss $7.8M; launches Medicaid pilot in Nevada","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16k vs $29k YoY; net loss $7.8M vs $7.9M; cash $102.4M funds operations through 2028.","Inaugural Medicaid pilot launched in Nevada; payer discussions across 13 states covering 33% of U.S. births.","PRIME study full results on track for publication in 2025; health economic data also forthcoming.","Appointed Dr. Tiffany Inglis as CMO and Marisol Urbano as Head of Commercial Operations.","SG&A rose to $5.7M from $5.4M due to commercial investments; R&D fell to $3.3M as PRIME study concluded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":71000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138116,"accession_number":"0001534969-25-000005","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics posts investor presentation at H.C. Wainwright conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["New investor presentation posted to corporate website on September 5, 2025.","Presented at H.C. Wainwright 27th Annual Global Investment Conference same day.","No specific financial or clinical data disclosed in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138115,"accession_number":"0000950170-25-103994","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q2 revenue $17K, net loss $8.0M, PreTRM progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17,000 vs $24,000 in Q2 2024; net loss $8.0M vs $8.3M.","Operating expenses $9.3M flat; R&D down 24% to $3.3M; SG&A up to $6.0M.","Cash $108.5M as of June 30, 2025, expected to fund through 2028.","PRIME study full results on track for publication this year; commercial traction with Medicaid plans.","Appointed Lee Anderson as CCO, Chuck Hyde as Head of Market Access, Jennifer Zibuda as Head of IR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":55000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155540,"accession_number":"0000950170-25-082539","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics announces annual meeting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. elected as Class I directors for three-year terms.","Auditor Ernst & Young ratified for FY2025 with 24,311,571 votes for, 2,691 against.","Quorum of 66.2% of eligible shares (24,314,265 of 36,701,381) present at June 5, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155539,"accession_number":"0000950170-25-067231","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics appoints Lee Anderson as Chief Commercial Officer; 30-year diagnostics veteran to lead PreTRM rollout","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.","Anderson previously led US Oncology Sales at Genomic Health (acquired by Exact Sciences) and was CCO at Biofidelity.","He will drive commercial adoption of the PreTRM test following positive PRIME study results.","Company is in commercial phase; Anderson brings over 30 years of healthcare sales and marketing leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155538,"accession_number":"0000950170-25-065654","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 revenue $38k, net loss $8.2M; payor discussions advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38k vs nil in prior year; net loss $8.2M vs $8.1M.","Cash and securities $114.2M as of March 31, 2025.","R&D expenses down 9% to $3.3M; SG&A up to $5.9M.","PRIME study met primary success criteria; engaging payors and planning Medicaid pilots.","Appointed Jeff Elliott to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":38000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174031,"accession_number":"0000950170-25-042005","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.","PRIME study: 25% reduction in neonatal morbidity/mortality index and 18% reduction in length of stay in modified ITT.","Full year 2024 revenue $77,000; net loss $32.9M vs $36.2M in 2023.","Raised $57.5M in Feb 2025 public offering; cash runway extended through 2028.","R&D expenses $3.1M in Q4, down 19% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174030,"accession_number":"0001193125-25-024518","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.","Gross proceeds expected to be ~$50M before underwriting discounts and commissions.","Underwriters have 30-day option to purchase up to an additional 1.875M shares.","Proceeds to expand US commercial infrastructure, accelerate EU expansion, fund PreTRM studies and potential FDA submission.","Existing cash plus net proceeds expected to fund operations through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174029,"accession_number":"0001193125-25-023577","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sera Prognostics terminates unused $50M ATM offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No shares of Class A common stock were sold under the ATM offering since its August 2024 inception.","Sales agreement with TD Cowen remains in force; no new sales without a fresh prospectus supplement.","Termination of the ATM prospectus supplement effective February 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174028,"accession_number":"0001193125-25-018170","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).","PRIME study met both co-primary endpoints: 25% reduction in neonatal morbidity (NMI) and 18% reduction in neonatal length of stay in mITT population.","ITT analysis: 20% reduction in NMI, 8% reduction in neonatal stay, and 20% reduction in NICU admissions.","PreTRM test classified 23.5% as higher risk; number needed to screen 3-4 to save one NICU day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174027,"accession_number":"0000950170-25-004909","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics files 8-K for new investor presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated investor presentation to its website on January 13, 2025.","Presentation to be shared at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025 at 9:45 a.m. PT.","Exhibit 99.1 investor presentation filed but specific content not provided in filing text.","No financial or operational updates disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174026,"accession_number":"0000950170-25-003021","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sera Prognostics PRIME study topline results published by SMFM","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.","Full results to be presented at SMFM 2025 Pregnancy Meeting on January 31, 2025.","Company to host conference call on February 6, 2025 at 12 p.m. ET to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190986,"accession_number":"0000950170-24-122288","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q3 revenue $29k, net loss $7.9M; PRIME study data locked","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $29k from $42k YoY; net loss widened to $7.9M from $7.2M.","Operating expenses $8.9M, up 8% YoY; SG&A $5.4M due to growth investments.","PRIME study database locked in Sept; results planned for 2025 conferences and journal submission.","Direct-to-consumer PreTRM testing via website launched Oct 1; TV awareness campaign with Dennis Quaid and Meg Ryan.","Ambient whole blood collection lowers cost of goods and boosts lab capacity for scalability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":53000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207455,"accession_number":"0001534969-24-000151","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q2 2024 net loss narrows to $8.3M; revenue drops to $24k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue was $24,000, down from $123,000 in Q2 2023.","Net loss improved 21% to $8.3M from $10.5M in Q2 2023.","Operating expenses decreased 20% to $9.3M; SG&A down 38% to $4.9M, R&D up 19% to $4.4M.","Published positive AVERT PRETERM TRIAL results; PRIME study database lock expected mid-September; NY State conditional approval for whole-blood collection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":24000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224880,"accession_number":"0001534969-24-000122","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics annual meeting elects directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 20,402,055 shares (64.4% of eligible) present at June 6, 2024 annual meeting.","Elected Critchfield (11.38M for), Lindgardt (9.38M for), Phillips (11.49M for) as Class III directors.","Ratified Ernst & Young as auditor for FY2024 with 20,391,485 votes for, 226 against, 10,344 abstain.","8,396,389 broker non-votes on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224879,"accession_number":"0001534969-24-000084","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 net loss narrows to $8.1M; net revenue nil after adjustments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue nil after periodic review of accounting estimates for older tests; gross revenue $39K vs $100K YoY.","Net loss $8.1M, improved 24% from $10.6M loss in Q1 2023.","Operating expenses $9.1M, down 20% YoY; SG&A $5.4M (-26%), R&D $3.7M (-10%).","Shipped first ambient whole blood collection kits to reduce COGS and expand access.","Submitted PRIME study interim analysis manuscript for peer-reviewed publication."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244141,"accession_number":"0001534969-24-000054","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sera Prognostics reports Q4/FY2023 results; DSMB stops PRIME study early for efficacy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DSMB recommended stopping PRIME enrollment after co-primary endpoints met significance at interim analysis; preparing manuscript.","Q4 2023 revenue $41K; full-year revenue $306K; net loss $7.9M (Q4) and $36.2M (FY), improved from prior year.","Operating expenses down to $8.9M (Q4) from $10.5M; SG&A reduced to $5.0M from $6.9M.","Cash and securities $79.9M as of Dec 31, 2023.","Progress on PreTRM sample collection enhancements; launching in certain geographies; building patient-facing products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261555,"accession_number":"0001534969-23-000127","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sera Prognostics amends Baker Bros. director nomination threshold to 19.9%","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment No. 2 to Side Letter with Baker Bros. Advisors LP executed Dec 6, 2023.","Baker Bros. must now beneficially own at least 19.9% of total voting power to nominate a director.","Previous threshold was lower; change raises bar for board appointment rights.","Amendment will be filed as exhibit to 2023 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261554,"accession_number":"0001534969-23-000121","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.","Company adopted DSMB recommendation; will stop enrollment to focus on analyzing and reporting available data.","CEO Zhenya Lindgardt described early stop as 'unexpected' and 'encouraging,' citing consistency with prior PREVENT and AVERT studies.","The PRIME trial is pivotal for the PreTRM® test, which aims to predict preterm birth risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261553,"accession_number":"0001534969-23-000111","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q3 net loss narrows to $7.2M; appoints permanent CEO and CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $42k vs $87k YoY; net loss $7.2M vs $10.7M in Q3 2022.","Operating expenses down to $8.2M from $11.3M; cash of $85M extends runway through most of 2027.","Board approved permanent CEO Zhenya Lindgardt and CFO Austin Aerts.","AVERT trial shows PreTRM test drove 2.5-week gestational age improvement and 18% reduction in severe neonatal morbidity.","New high-low risk predictor product enters next phase of market research; care coordination offering launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":265000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278775,"accession_number":"0001534969-23-000096","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics posts investor presentation; no material details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["New investor presentation posted to corporate website on September 25, 2023.","No specific financial metrics, guidance, or operational changes provided in filing.","Presentation content not available for review; filing is routine FD disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278774,"accession_number":"0001534969-23-000091","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Q2 revenue $123K, net loss $10.5M; appoints interim CEO and CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123,000 (Q2 2023) vs $78,000 (Q2 2022), up 58% YoY but still minimal.","Net loss $10.5M vs $11.5M; operating expenses $11.6M vs $11.8M.","Cash, equivalents, and securities $92.1M as of June 30, 2023.","Appointed Zhenya Lindgardt interim President/CEO and Austin Aerts interim CFO; headcount reductions in commercial team.","Engaged strategy firm to evaluate paths to enhance revenue at reduced cost for PreTRM Test commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":223000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278773,"accession_number":"0001534969-23-000086","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sera Prognostics CMO Michael R. Foley resigns, moves to consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Michael R. Foley resigned effective June 30, 2023.","Entered consulting agreement July 1, 2023: $500/hour, up to 12 hours/week.","Equity awards continue vesting during 24-month consulting term.","Either party may terminate with 90 days' written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297036,"accession_number":"0001534969-23-000069","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Sera Prognostics shareholders approve officer exculpation, re-elect directors, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Kim Kamdar, Sandra Lawrence, and Ryan Trimble as Class II directors; each received >17M votes for.","Ratified Ernst & Young as independent auditor for FY 2023 with 20M votes for, only 50 against.","Approved amendment to certificate of incorporation to permit officer exculpation for breach of fiduciary duty of care; effective June 9, 2023.","Quorum of 21,837,079 shares (73.66%) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297035,"accession_number":"0001534969-23-000057","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sera Prognostics CFO and CCO depart; interim leadership appointed; commercial restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jay Moyes resigns effective June 7, 2023; Austin Aerts appointed interim CFO.","CCO Nadia Altomare resigns effective June 9, 2023, moves to consulting role.","Interim President and CEO Zhenya Lindgardt appointed May 15, 2023; leads cost optimization.","Company engages leading strategy house to evaluate pathways for revenue growth at lower costs.","Select headcount reductions in commercial organization to focus on near-term lucrative opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297034,"accession_number":"0001534969-23-000055","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Gregory Critchfield to retire June 8; Transition Agreement provides $584K severance plus bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Retirement as President, CEO and Chairman effective June 8, 2023.","Severance of $584,000 (one year base salary) and pro rata bonus of $131,400.","Unvested stock options/equity forfeited; vested options remain exercisable for remaining term.","COBRA health coverage for up to 12 months or until new coverage.","No immediate successor named in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297033,"accession_number":"0001534969-23-000053","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sera Prognostics CEO Greg Critchfield to retire June 8; Zhenya Lindgardt named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Gregory Critchfield retires after 12 years, effective June 8, 2023; remains on board.","Board member Zhenya Lindgardt appointed Interim CEO; Kim Kamdar named Board Chair.","Critchfield led company from inception through PreTRM test launch; Lindgardt has experience at Uber and BCG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297032,"accession_number":"0001534969-23-000050","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 revenue $100K, net loss $10.6M; AVERT trial positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $100K, up 163% from $38K in Q1 2022.","Net loss narrowed to $10.6M from $12.2M YoY.","Cash and securities $100M; R&D spend $4.1M (up), SG&A $7.3M (down).","Positive AVERT PRETERM TRIAL topline results announced in February.","Physician orders increasing; PRIME study interim look expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317402,"accession_number":"0001534969-23-000028","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics reports Q4 net loss $9.7M, revenue $65k; positive AVERT PRETERM trial results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $9.7M vs $12.5M in Q4 2021; revenue $65k vs $26k.","Full year 2022 revenue $268k; cash and securities $104.0M at Dec 31, 2022.","AVERT PRETERM trial showed generalizability of PreTRM test-and-treat strategy improving neonatal outcomes.","PRIME study surpassed required 2,800 subject enrollment; interim look analysis expected by year end.","R&D expenses $3.5M in Q4; SG&A $6.9M down from $9.5M due to sales streamlining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317401,"accession_number":"0001534969-23-000021","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sera Prognostics has no exposure to Silicon Valley Bank; no cash or banking relationship","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company does not hold any cash at Silicon Valley Bank (SVB).","Company has no banking relationship with SVB.","Management believes there is no exposure to SVB liquidity concerns following FDIC receivership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317400,"accession_number":"0001534969-23-000003","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sera Prognostics amends Baker Bros. director nomination right; ownership threshold raised to 9.9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Side Letter with Baker Bros. Advisors LP increases ownership threshold for director nomination from 4.0% to 9.9% of outstanding voting power.","Nomination right suspended while Baker Bros. designee serves on board; right revives when designee leaves.","Amendment dated February 16, 2023; filed as exhibit to 10-K for year ended December 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335634,"accession_number":"0001534969-22-000129","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.","Operating expenses $11.3M, up from $9.5M; R&D $4.2M, SG&A $7.0M.","Cash, equivalents & securities $111.2M at Sept 30, 2022.","Banner Health signed for PreTRM test under Medicaid plan (~300k members); revenue possible Q4 2022.","PRIME study on track; interim look expected 2023; preeclampsia validation data by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":203000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353064,"accession_number":"0001534969-22-000122","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.","Net loss of $11.5M ($0.29/share) vs $6.3M a year ago; cash & securities at $121M as of June 30.","PreTRM test now collects blood at 18-20 weeks; sensitivity ~90%, NPV 99% for preterm risk.","Company streamlined operations to fund operations into 2026 without additional financing.","Contracted several new self-insured employer plans for PreTRM testing as an advanced pregnancy benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":116000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370719,"accession_number":"0001534969-22-000107","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K/A","filed_at":"2022-06-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sera Prognostics adds Dr. Jane Barlow to nominating and governance committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Jane Barlow appointed to the nominating and governance committee effective June 27, 2022.","This 8-K/A amends the April 12, 2022 8-K that reported Barlow's director appointment.","No other changes from the original filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370718,"accession_number":"0001534969-22-000106","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K/A","filed_at":"2022-06-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sera Prognostics adds Director Sandra Lawrence to audit committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sandra A.J. Lawrence was appointed to the Board effective November 29, 2021.","On June 27, 2022, she was appointed to the audit committee of the Board.","No other changes from the original November 30, 2021 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370717,"accession_number":"0001534969-22-000105","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K/A","filed_at":"2022-06-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sera Prognostics fills missing committee assignment for director Lindgardt","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zhenya Lindgardt appointed to compensation committee effective June 27, 2022.","This amendment supplements the November 8, 2021 8-K that announced her director election.","No other changes to prior disclosure; committee role was previously undetermined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370722,"accession_number":"0001534969-22-000078","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics stockholders elect three Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jane F. Barlow (15,626,263 for), Mansoor R. Mirza (15,256,849 for), Marcus Wilson (15,420,794 for) as Class I directors.","Ratified Ernst & Young as independent auditor for FY2022 with 23,098,495 shares for, 7,502 against, 5,029 abstaining.","Meeting held June 3, 2022; all proposals carried with routine vote totals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370721,"accession_number":"0001534969-22-000067","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 net loss $12.2M; revenue $38k; PreTRM orders rise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38k in Q1 2022 vs $13k in Q1 2021; still minimal.","Net loss widened to $12.2M from $6.4M; operating expenses $12.3M vs $6.0M.","Cash and securities total $129.9M as of March 31, 2022.","Simplified PreTRM ordering process; order trends improving into Q2.","Preeclampsia biomarker validation expected mid-2022; PRIME study on track for 2023 interim readout."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":38000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370720,"accession_number":"0001534969-22-000048","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sera Prognostics appoints Dr. Jane F. Barlow to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jane F. Barlow appointed as Class I Director effective April 11, 2022; term expires at 2022 annual meeting.","Dr. Barlow brings experience from CVS Health, Medco, and boards of ContraFect, Viracta, Point Health.","Granted non-qualified stock option with $240,000 grant date fair value, vesting monthly over 36 months.","Entitled to annual cash retainer of $35,000 for non-employee director service, prorated.","Company entered into standard indemnification agreement with Dr. Barlow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389772,"accession_number":"0001534969-22-000033","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q4 2021 revenue $26k, net loss $12.5M; losses widen as commercial ops scale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue rose to $26k from $6k YoY; net loss of $12.5M vs $5.4M.","Full-year 2021 revenue $82k, total operating expenses $35.5M (up from $18M).","Cash and securities totaled $139.9M as of Dec 31, 2021.","CMS set Medicare payment rate of $750 for PreTRM test; added to NASDAQ Biotechnology Index.","R&D spend increased to $3.1M in Q4; SG&A jumped to $9.5M on higher headcount and public company costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407739,"accession_number":"0001534969-21-000023","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2021-11-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sera Prognostics appoints Sandra A.J. Lawrence to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed effective Nov 29, 2021 as Class II director with term expiring at 2023 annual meeting.","Received non-qualified stock option with $240,000 grant date fair value, vesting in 36 monthly installments.","Entitled to annual cash retainer of $35,000, prorated for 2021 service.","Lawrence brings extensive board experience including Evergy, American Shared Hospital Services, and Recology.","Former EVP/CFO of Children's Mercy Hospital; holds MBA from Harvard Business School."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407738,"accession_number":"0001534969-21-000017","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q3 net loss widens to $9.9M; cash $82.5M; salesforce scaling to 26 reps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23K vs $5K YoY; net loss $9.9M vs $5.1M YoY.","Operating expenses $9.5M (R&D $2.7M, SG&A $6.7M) up from $4.6M due to scaling commercial ops and public company costs.","Cash & equivalents $82.5M plus $67.5M available-for-sale securities.","Salesforce now 26 reps; appointed Paul Kearney as Chief Data Officer, Zhenya Lindgardt to Board, Woodrow Myers as advisor.","Published health economic study showing PreTRM test could reduce $54M in costs; clinical validation study published."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":56000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-09T23:59:59+00:00|407738"}